文献速递衰弱、肌少症与跌倒认知障碍与谵妄老年综合评估

阿尔茨海默病血液生物标志物与社区老年人12年肌肉力量轨迹:一项队列研究

Blood biomarkers of Alzheimer's disease and 12-year muscle strength trajectories in community-dwelling older adults: a cohort study.
PubMed 文献 · Lancet Healthy Longev · 2025-05-22

p-tau181、p-tau217和神经丝轻链较高还与握力加速下降相关,且校正MMSE后未减弱。女性中生物标志物与肌肉力量下降的关联更强。

要点

  • p-tau181、p-tau217、NfL和GFAP较高与椅子站立表现加速下降相关。
  • p-tau181、p-tau217和NfL较高与握力加速下降相关,校正MMSE后仍显著。
  • 女性中生物标志物与肌肉力量下降的关联强于男性,尤其椅子站立测试。

核心结论

  • 阿尔茨海默病相关血液生物标志物可能有助于估计老年人进行性肌肉力量下降。
  • 这些生物标志物可能帮助识别需要早期干预以预防肌少症的个体。

研究设计与样本

  • 基于瑞典SNAC-K前瞻性队列研究,纳入60岁及以上社区居住无痴呆参与者。
  • 分析基线至第四次随访(2001年3月21日至2016年12月31日)数据。
  • 测量七种阿尔茨海默病相关血液生物标志物:总tau、p-tau181、p-tau217、淀粉样β40和42、神经丝轻链、GFAP。
  • 肌肉力量通过握力和椅子站立测试测量,采用线性混合模型分析基线生物标志物与肌肉力量轨迹的关联。

主要发现

  • 校正MMSE评分后上述关联减弱;p-tau181、p-tau217和神经丝轻链较高还与握力加速下降相关,校正MMSE后未减弱。

临床怎么用

  • 在老年医学评估中,可考虑检测阿尔茨海默病相关血液生物标志物以辅助识别肌肉力量进行性下降的高风险老年人。
  • 对于生物标志物升高的老年人,尤其女性,应加强握力和椅子站立表现的监测,并尽早开展预防肌少症的干预。
  • 认知功能评估(如MMSE)有助于解释生物标志物与椅子站立表现下降的关联,但握力下降的关联独立于认知功能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Age-related muscle function decline is a major impediment to healthy ageing. We aimed to investigate the association between a panel of Alzheimer's disease-related biomarkers and longitudinal trajectories of muscle strength, while exploring the influence of cognitive function. METHODS: In this cohort study, we gathered data from the Swedish National study on Aging and Care in Kungsholmen (SNAC-K), an ongoing prospective study that includes adults aged 60 years and older, from central Stockholm, Sweden. We included data from baseline to the fourth follow-up (March 21, 2001, to Dec 31, 2016). Seven Alzheimer's disease-related blood biomarkers were measured in dementia-free, community dwelling participants: total tau, phosphorylated tau181 (p-tau181), phosphorylated tau217 (p-tau217), amyloid β 40 and 42, neurofilament light chain, and glial fibrillary acidic protein (GFAP). Muscle strength was measured through the handgrip strength and chair-stand tests. Linear mixed models were used to explore the association between baseline Alzheimer's disease-related biomarkers and muscle strength trajectories. FINDINGS: The baseline SNAC-K cohort included 3363 individuals, of whom 1953 participants were included in our analyses (mean age 70·2 [SD 9·1] years; 780 [39·9%] male and 1173 [60·1%] female participants). In adjusted models, higher concentrations of p-tau181 (β per year 0·93 [95% CI 0·71 to 1·16]; p<0·0001), p-tau217 (β per year 1·31 [1·03 to 1·58]; p<0·0001), neurofilament light chain (β per year 0·76 [0·56 to 0·96]; p<0·0001), and GFAP (β per year 0·37 [0·21 to 0·53]; p<0·0001) were associated with an accelerated decline of chair-stand performance over time. The adjustment for Mini-Mental State Examination (MMSE) score led to the attenuation of these associations. Higher concentrations of p-tau181 (β per year -0·12 [95% CI -0·17 to -0·07]; p<0·0001), p-tau217 (β per year -0·13 [-0·20 to -0·07]; p<0·0001), and neurofilament light chain (β per year -0·05 [-0·09 to -0·001]; p=0·047) were also associated with faster handgrip strength decline, with no attenuation after adjusting for MMSE score. Sex-specific differences were observed, with female participants showing a stronger association between biomarker concentrations and muscle strength decline than male participants, particularly in the chair-stand test. INTERPRETATION: Our findings suggest that blood Alzheimer's disease-related biomarkers might help estimate progressive muscle strength decline among older adults, elucidating the influence of brain pathology and cognitive ageing on this association. These Alzheimer's disease-related biomarkers could aid in identifying individuals for early intervention to prevent sarcopenia. FUNDING: The Swedish Research Council, the Swedish Ministry of Health and Social Affairs, and the County Councils and Municipalities.

来源:Lancet Healthy Longev,查看原文。版权归原作者所有。

引用

  1. Ornago AM, Pinardi E, Grande G, et al. Blood biomarkers of Alzheimer's disease and 12-year muscle strength trajectories in community-dwelling older adults: a cohort study. Lancet Healthy Longev. 2025. PMID: 40414227. doi:10.1016/j.lanhl.2025.100715

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。